|
4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Acute myeloid leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2006-07-20 00:00:00 |
| Sponsor | Johnson & Johnson Pharmaceutical Research & Dev,;920 U S Highway 202, P.O. Box 300;Raritan, New Jersey, 08869 |
